Facebook      Twitter

blank

blank

ONLINE LEARNING CENTER

HIV PRE-EXPOSURE PROPHYLAXIS: A REVIEW (17HH02)

Shobha Swaminathan, MD, Debra Chew, MD and Lisa L. Dever, MD Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School


 
 
 

Release Date: December 1, 2014
Expired: November 30, 2016
Activity Code: 17HH02

IMPORTANT:
CREDIT IS NO LONGER AVAILABLE FOR THIS ACTIVITY.
This content is being provided for informational purposes only.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.
As seen in the Winter 2014 edition of


ACTIVITY INFORMATION

Sponsor

Sponsored by François-Xavier Bagnoud Center, School of Nursing, Rutgers, The State University of New Jersey and the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences.

Funding

This activity is supported by an educational grant from the New Jersey Department of Health (NJDOH)—Division of HIV, STD and TB Services, through an MOA titled “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Statement of Need

Much research has centered on the use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) in the prevention and spread of new HIV infection. PrEP is the use of antiretroviral (ARV) medications prior to HIV exposure, and PEP is the use of ARV medications after a possible HIV exposure to prevent primary HIV infection. PrEP is now recommended for use by HIV discordant couples to prevent the non-infected partner from acquiring HIV during unprotected sexual behaviors, adult men who have sex with other men (MSM), and for adult injection substance users at risk of primary HIV infection. PEP has been historically used for intermittent use by serodiscordant couples, for treatment of persons following possible HIV exposure from sexual assault, and for those possibly exposed to HIV through occupational experiences (needle-stick or mucosal exposure). On May 14, 2014, the United States Public Health Service released the first comprehensive clinical practice guidelines for PrEP. The guidelines were developed by a federal inter-agency working group led by CDC, and reflect input from providers, HIV patients, partners, and affected communities.

This activity will assist health care providers with PrEP implementation, increasing their general knowledge around the use of PrEP and optimizing the opportunity to prevent new infections for those who are with a sero-discordant partner.

Target Audience

This activity is designed for physicians, nurses, health educators, and other health care professionals in New Jersey who are involved in the care of people infected with HIV and their non-HIV infected partners.

Method of Participation

Participants should read the learning objectives, review the activity in its entirety, and then complete the self-assessment test, which consists of a series of multiple-choice questions. Upon completing this activity as designed and achieving a passing score of 70% or more on the self-assessment test and submitting a course evaluation, participants will receive a printable credit statement.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe at least 3 different studies that led to the CDC recommendation of PrEP use in the United States.
  2. Describe the baseline and follow-up procedures that need to be done when starting someone on PrEP.
  3. Identify who should and who should not be advised to take PrEP, as per CDC recommendations.
  4. Identify resources from the CDC and the CCC to help manage PrEP with your patients.

Faculty

Activity Directors/CME Academic Advisors

Shobha Swaminathan, MD, Assistant Professor, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Margaret Evans, MSN, RN, CCOE Primary Nurse Planner; Nurse Manager for Education and Performance Improvement at Robert Wood Johnson Medical Group.

Planning Committee

Mary Jo Hoyt, MSN, Director, Education and Capacity Development, FXB Center, Rutgers

John Nelson, PhD, CPNP, Program Director, AETC NRC, FXB Center, Rutgers

Andrea Norberg, MS RN, Executive Director, FXB Center, Rutgers

Joanne Phillips, MS RN, Education Specialist, FXB Center, Rutgers

Michelle Thompson, Program Manager, FXB Center, Rutgers

Elizabeth Ward, MSJ, Executive Director, Rutgers CCOE

Activity Authors

Shoba Swaminathan, MD, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Debra Chew, MD, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Lisa L. Dever, MD, Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School

Accreditation

Credit is no longer available for this activity.

Peer Review

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by John Nelson, PhD, CPNP and Joanne Phillips, MS, RN.

Field Test:
This activity was field tested for time required for participation by Noa’a Shimoni, MD, MPH, David Abel, DO, Howard A. Grossman, MD, Anna M. Haywood, MSN, RN, Juanita Howell, MSN, RN, and Laura Bogert, BSN, RN.

Disclosure Disclaimer

In accordance with the disclosure policies of Rutgers University and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.

Disclosure Declarations

The authors, activity directors, all other planning committee members, peer reviewers and field testers have no relevant financial relationships to report.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Content Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NJDOH – Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or Rutgers University. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Copyright © 2014 Rutgers University

All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers University.

Privacy Policy

To review Rutgers' privacy policy, please see: http://ccoe.rbhs.rutgers.edu/general/privacypolicy.html

Please direct CE related or technical questions to Rutgers at 973-972-4267 or email ccoe@ca.rutgers.edu.


 

© Copyright 2017, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy